GRAIL faces financial challenges but holds significant growth potential with its Galleri cancer-screening test. Click here to ...

Investors have circled back to healthcare stocks this year, and they’re likely to stick around. If they came for the ...

2 Since then, aside from the Illumina/Grail transaction, the Commission called in a small number of concentrations. The ...

Number of Hedge Fund Holders: 56 Illumina, Inc. (NASDAQ:ILMN) offers sequencing and array based solutions for genetic and ...

The Rome Study demonstrated the value of extensive sequencing and discussion of individual cancer cases to offer tailored therapeutic choices.

The organisms found in the microbiome outnumber human cells. This makes the microbiome a key target to aid in our ...

Amid rising agricultural complexity and the push for sustainability, genomics is at the forefront of innovation in breeding ...

The Dutch competition watchdog is seeking beefed-up powers to probe more small deals that risk crushing competition in ...

ANGLE ANNOUNCES NEXT GENERATION SEQUENCING ASSAY AGREEMENT WITH NUPROBE Option for exclusive licence to highly sensitive NGS ...